CN114214377A - Phosphatidyl-agaropectin oligosaccharide and preparation method thereof - Google Patents
Phosphatidyl-agaropectin oligosaccharide and preparation method thereof Download PDFInfo
- Publication number
- CN114214377A CN114214377A CN202111600499.6A CN202111600499A CN114214377A CN 114214377 A CN114214377 A CN 114214377A CN 202111600499 A CN202111600499 A CN 202111600499A CN 114214377 A CN114214377 A CN 114214377A
- Authority
- CN
- China
- Prior art keywords
- phosphatidyl
- oligosaccharide
- agaropectin
- agar
- agar oligosaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001817 Agar Polymers 0.000 title claims abstract description 55
- 229920001542 oligosaccharide Polymers 0.000 title claims abstract description 55
- 150000002482 oligosaccharides Chemical class 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 239000008272 agar Substances 0.000 claims abstract description 39
- 238000006243 chemical reaction Methods 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 32
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims abstract description 28
- JWMBOBQNPBCYER-UHFFFAOYSA-N 4-[(4,8-dihydroxy-2,6-dioxabicyclo[3.2.1]octan-3-yl)oxy]-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound OC1C(CO)OC(O)C(O)C1OC1C(O)C(C2O)OCC2O1 JWMBOBQNPBCYER-UHFFFAOYSA-N 0.000 claims abstract description 24
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical group OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 claims abstract description 22
- 102000011420 Phospholipase D Human genes 0.000 claims abstract description 12
- 108090000553 Phospholipase D Proteins 0.000 claims abstract description 12
- 239000002502 liposome Substances 0.000 claims abstract description 6
- 230000009471 action Effects 0.000 claims abstract description 3
- 239000013543 active substance Substances 0.000 claims abstract description 3
- 238000012377 drug delivery Methods 0.000 claims abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000012074 organic phase Substances 0.000 claims description 12
- 102000004190 Enzymes Human genes 0.000 claims description 11
- 108090000790 Enzymes Proteins 0.000 claims description 11
- 239000008346 aqueous phase Substances 0.000 claims description 9
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000012071 phase Substances 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 5
- 229920000936 Agarose Polymers 0.000 claims description 4
- 101710110830 Beta-agarase Proteins 0.000 claims description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 4
- SKTCDJAMAYNROS-UHFFFAOYSA-N methoxycyclopentane Chemical compound COC1CCCC1 SKTCDJAMAYNROS-UHFFFAOYSA-N 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 claims description 4
- HNAGHMKIPMKKBB-UHFFFAOYSA-N 1-benzylpyrrolidine-3-carboxamide Chemical compound C1C(C(=O)N)CCN1CC1=CC=CC=C1 HNAGHMKIPMKKBB-UHFFFAOYSA-N 0.000 claims description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical group COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims description 2
- 235000021314 Palmitic acid Nutrition 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 239000007853 buffer solution Substances 0.000 claims description 2
- OBNCKNCVKJNDBV-UHFFFAOYSA-N butanoic acid ethyl ester Natural products CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 claims description 2
- 230000000593 degrading effect Effects 0.000 claims description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 2
- 235000020778 linoleic acid Nutrition 0.000 claims description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 2
- 125000005313 fatty acid group Chemical group 0.000 claims 1
- 238000005809 transesterification reaction Methods 0.000 abstract description 13
- 229930182470 glycoside Natural products 0.000 abstract description 10
- -1 phosphatidyl glycoside Chemical class 0.000 abstract description 10
- 150000003904 phospholipids Chemical class 0.000 abstract description 10
- 230000015572 biosynthetic process Effects 0.000 abstract description 7
- 238000003786 synthesis reaction Methods 0.000 abstract description 6
- 239000000463 material Substances 0.000 abstract description 5
- 238000005538 encapsulation Methods 0.000 abstract description 4
- 238000011160 research Methods 0.000 abstract description 4
- 239000006228 supernatant Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 7
- 238000004549 pulsed laser deposition Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 6
- XASQSRDYYCWSME-NWCCWNDLSA-N (2S,3R,4S,5R,6R)-4-[[(1S,3S,4S,5S,8R)-8-[(2S,3R,4S,5S,6R)-4-[[(1S,3S,4S,5R,8R)-4,8-dihydroxy-2,6-dioxabicyclo[3.2.1]octan-3-yl]oxy]-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-hydroxy-2,6-dioxabicyclo[3.2.1]octan-3-yl]oxy]-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O[C@@H]2O[C@H]3CO[C@H]([C@@H]3O[C@@H]3O[C@H](CO)[C@H](O)[C@H](O[C@@H]4O[C@H]5CO[C@H]([C@@H]5O)[C@@H]4O)[C@H]3O)[C@@H]2O)[C@@H]1O XASQSRDYYCWSME-NWCCWNDLSA-N 0.000 description 5
- 229930182830 galactose Natural products 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000002051 biphasic effect Effects 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000003892 spreading Methods 0.000 description 3
- 230000007480 spreading Effects 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical group ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000002144 chemical decomposition reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000009144 enzymatic modification Effects 0.000 description 2
- 238000000105 evaporative light scattering detection Methods 0.000 description 2
- 150000002327 glycerophospholipids Chemical class 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 108010045649 agarase Proteins 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000021617 central nervous system development Effects 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 150000004665 fatty acids Chemical group 0.000 description 1
- 150000002190 fatty acyls Chemical group 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 125000001095 phosphatidyl group Chemical group 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000006277 sulfonation reaction Methods 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/12—Disaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/02—Monosaccharides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6436—Fatty acid esters
- C12P7/6445—Glycerides
- C12P7/6472—Glycerides containing polyunsaturated fatty acid [PUFA] residues, i.e. having two or more double bonds in their backbone
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6436—Fatty acid esters
- C12P7/6445—Glycerides
- C12P7/6481—Phosphoglycerides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The invention discloses a phosphatidyl-agar oligosaccharide which is prepared by the following method: phosphatidyl choline and agar oligosaccharide are catalyzed by phospholipase D in a two-phase reaction system to generate transphosphatidylation action, and the phosphatidyl-agar oligosaccharide is synthesized; the agar oligosaccharide is selected from D-galactose and neoagarobiose; the phospholipase D is selected from PLDr 34. The phosphatidyl-agar oligosaccharide is a novel phosphatidyl glycoside, phospholipid can be used for preparing liposome materials, and a transesterification product has an encapsulation function, so that the phosphatidyl-agar oligosaccharide has good application prospects in the aspects of encapsulation and transportation, and can be used as an active substance to be applied to the aspects of liposome preparation, drug delivery and the like. The invention explores the generation conditions of the transphosphatidylation of phosphatidylcholine and agar oligosaccharide, synthesizes novel phosphatidyl glycoside, provides reasonable guidance for the synthesis of other phosphatidyl glycoside, and has certain research prospect.
Description
Technical Field
The invention relates to a phosphatidyl-agaropectin oligosaccharide and a preparation method thereof, belonging to the technical field of phosphatidyl glycoside.
Background
The sea is a treasure house and is a potential source of a plurality of natural bioactive substances. In all tissues, phospholipids, which are basic substances of life, are composed of a hydrophilic head group and a hydrophobic tail group, and are classified into glycerophospholipids and sphingolipids according to their connection modes, wherein the content of Phosphatidylcholine (PC) in the glycerophospholipids is most abundant.
Phospholipids can not only participate in the formation of cell membranes and maintain their biological functionality, but also play an important role in cell micelles and organelles, for example, part of phospholipids are precursors of various anti-inflammatory compounds, can regulate systemic inflammation, and provide protection against chronic diseases. Phospholipids can be modified under various conditions such as hydrogenation, acetylation, sulfonation and enzymatic modification, and the first three chemical modification methods are applied to the improvement of physical properties of membranes, and the enzymatic modification is modification of hydrophilic head groups or hydrophobic fatty acyl chains, such as phospholipase D (PLD) mediated transphosphatidylation. Multiple studies in animal models have shown that modified phospholipids have higher bioavailability and bioactivity, especially in terms of their effect on plasma and liver lipid levels.
One important product after phospholipid modification is phosphatidyl glycoside, and most of the glycosylated phospholipids are rich in lipid rafts or microdomains and play an important role in various cellular processes. In rodent brain, expression of phosphatidylglucoside (PtdGlc) is developmentally regulated. PtdGlc is most strongly expressed in radial glia in early rat brain development and is considered to be a good cell surface marker for stem cells. Lysophosphatidylglucoside (LPGlc) can act as a guide wire for extending axons during central nervous system development by activating the AG-like protein-coupled receptor (GPR) 55 of spinal sensory axons.
At present, most of the research on the aspect of phosphatidyl glycoside focuses on glucose, fructose, mannose and raffinose, and no deep research on agar oligosaccharide exists.
Agar is used as a raw material to prepare the marine functional oligosaccharide with the polymerization degree of 2-20. The preparation method of the agar oligosaccharide mainly comprises a chemical degradation method and a biological enzyme degradation method. Chemical methods are applied more, but still have some disadvantages, such as non-uniform product composition, complicated operation, easy environmental pollution, etc. The biological enzyme degradation method is to adopt specific agarase to hydrolyze glycosidic bonds on agar sugar chains so as to obtain specific agar oligosaccharides, and has the advantages of high catalytic efficiency, good product specificity, mild reaction conditions, no pollution and the like.
Disclosure of Invention
Aiming at the prior art, the invention provides a novel phosphatidyl glycoside-phosphatidyl-agaropectin oligosaccharide and a preparation method thereof. The preparation method has the advantages of short reaction route, simple steps, high yield, no toxic chemicals involved in the synthesis process and high stability of the transesterification product.
The invention is realized by the following technical scheme:
a phosphatidyl-agar oligosaccharide is prepared by the following method: phosphatidyl choline and agar oligosaccharide are catalyzed by phospholipase D in a two-phase reaction system to generate transphosphatidylation action, and the phosphatidyl-agar oligosaccharide is synthesized; the agar oligosaccharide is selected from D-galactose and neoagarobiose; the phospholipase D is selected from PLDr 34.
Further, the fatty acid chains on the phosphatidylcholine are palmitic acid C16:0 and linoleic acid C18:2, respectively.
Further, the phosphatidylcholine is dissolved in an organic solvent to serve as an organic phase; the organic solvent is selected from methyl ether, ethyl ether, cyclopentyl methyl ether, ethyl acetate, butyl acetate or ethyl butyrate; the concentration of the phosphatidylcholine is 10-100 mg/mL.
Further, the agar oligosaccharides are dissolved in an aqueous solution as an aqueous phase; the water solution is selected from citric acid-sodium citrate buffer solution with the pH value of 4.0-6.0.
The agar oligosaccharide can be prepared by a biological enzymolysis method or a chemical degradation method.
Furthermore, the neoagarobiose is prepared by degrading agarose by beta-agarase AgWH50B (Access Number: KY 417136) and/or beta-agarase AgWH50C (Access Number: KC 913197) obtained by screening in the subject group of the inventor of the invention. The specific preparation method can be as follows: taking 1% agarose solution (g/ml) as a substrate, adding 2.0 g of AgWH50B crude enzyme, carrying out water bath reaction at 37 ℃ for 12 h, carrying out boiling water bath for 10 min, then adding 1.5 g of AgWH50C crude enzyme, carrying out water bath reaction at 37 ℃ for 12 h, carrying out boiling water bath for 10 min, centrifuging, taking supernatant, concentrating and drying to obtain the neoagarobiose. The neoagarotetraose can be prepared by the following method: taking a 1-2% agarose solution (g/ml) as a substrate, adding 2.0 g AgWH50B crude enzyme, reacting in a water bath at 37 ℃ for 12 h, boiling for 10 min, centrifuging to obtain a supernatant, concentrating and drying to obtain the neoagarotetraose.
Further, in the two-phase reaction system, the molar ratio of the phosphatidylcholine to the agar oligosaccharide is 1: 45-55, preferably 1: 50; the volume ratio of the organic phase to the aqueous phase is 1: 0.8-1.2, preferably 1: 1; the enzyme adding amount of the phospholipase D is 1.0-1.5U, and 1.4U is preferred.
Further, the specific reaction conditions for catalyzing transphosphatidylation are as follows: the reaction system is subjected to water bath reaction at 37-42 ℃ for 8-12 h; and centrifuging to take the supernatant after the reaction is finished, dissolving the product phosphatidyl-agar oligosaccharide in an upper organic phase, and blowing nitrogen to obtain the phosphatidyl-agar oligosaccharide.
The phosphatidyl-agar oligosaccharide is a novel phosphatidyl glycoside, phospholipid can be used for preparing liposome materials, and a transesterification product has an encapsulation function, so that the phosphatidyl-agar oligosaccharide has a good application prospect in the aspects of encapsulation and transportation, and can be used as an active substance (such as a drug carrier, a liposome membrane material and the like) to be applied to the aspects of liposome preparation, drug delivery and the like.
The invention explores the occurrence conditions of the transphosphatidylation of phosphatidylcholine and agar oligosaccharide, and the screened agar oligosaccharide with higher substrate preference is connected to the phosphatidylcholine through the transphosphatidylation, so that a novel phosphatidyl glycoside, namely phosphatidyl-agar oligosaccharide, is synthesized, reasonable guidance is provided for the synthesis of other phosphatidyl glycosides, and the method has a certain research prospect. The preparation method of the invention is a double-enzyme synthesis method, which greatly reduces the production cost.
The various terms and phrases used herein have the ordinary meaning as is well known to those skilled in the art.
Drawings
FIG. 1: and (3) a TLC result graph of transesterification reaction of phosphatidylcholine and agar oligosaccharides with different polymerization degrees, wherein PC represents phosphatidylcholine, and 1, 2, 3 and 4 respectively represent transesterification reaction results of PC and D-galactose, neoagarobiose, neoagarotetraose and 1-15 AOS.
FIG. 2: chemical structure of phosphatidylcholine.
FIG. 3: chemical structure diagram of phosphatidyl-D galactose.
FIG. 4: chemical structure diagram of phosphatidyl-neoagarobiose.
FIG. 5: the results of mass spectrometry of phosphatidyl-D galactose are shown schematically.
FIG. 6: the results of mass spectrometry of phosphatidyl-neoagarobiose are shown schematically.
FIG. 7: and (3) a result chart of analyzing the phosphatidyl-agaropectin oligosaccharide by an HPLC-ELSD method.
Detailed Description
The present invention will be further described with reference to the following examples. However, the scope of the present invention is not limited to the following examples. It will be understood by those skilled in the art that various changes and modifications may be made to the invention without departing from the spirit and scope of the invention.
The instruments, reagents, materials and the like used in the following examples are conventional instruments, reagents, materials and the like in the prior art and are commercially available in a normal manner unless otherwise specified. Unless otherwise specified, the experimental methods, detection methods, and the like described in the following examples are conventional experimental methods, detection methods, and the like in the prior art.
The phosphatidylcholine used in the present invention is Soy PC (95%) (SPC, 441601G-50G-I-175, Avanti Polar Lipids).
The 1-15AOS used in the invention is mixed sugar of agar monosaccharide to pentadecaose, and 1-15 agar oligosaccharide (1500 Da, Qingdao Bozhi Hui Virginian Biotech Co., Ltd.).
The phospholipase D used in the invention is PLDr34 (Access Number: MN 604233) (the enzyme is described in another patent application of the applicant of the invention, CN 110564708A, namely the phospholipase shown in SEQ ID NO.1 in the specification of CN 110564708A), and the amino acid sequence of the phospholipase D is shown as follows.
Amino acid sequence of PLDr 34:
MIISFRLSRPARAALICALALTVLPASPATAADAATPHLDAVERTLREVSPGLEGEVWERTAGNRLDAGADDPAGWLLQTPGCWGDAGCRDRVGTRRLLAKMTENISRATRTVDISTLAPFPNGAFQDAIVAGLKSSAARGNKLTVRVLVGAAPIYHMNVLPSKYRDELVAKLGADARNVDLNVASMTTSKTSFSWNHSKLLVVDGQSVITGGINDWKDDYLETAHPVADVDLALRGPAAASAGRYLDELWSWTCQNRNNIAGVWFASSNGTACMPAMAKDTAPAAPPAAPGDVPAIAVGGLGVGIKRSDPSSAFRPTLPSAADTKCVVGLHDNTNADRDYDTVNPEESALRTLISSAKGHIEISQQDVNATCPPLPRYDIRVYDALAARMAAGVKVRIVVSDPANRGAVGSGGYSQIKSLSEISDTLRDRLALLTGDQGAAKATMCSNLQLATFRSSKSPTWADGHPYAQHHKVVSVDDSAFYIGSKNLYPAWLQDFGYIVESPGAAQQLDAQLLSPQWTHSKETATVDYERGLCHI。
experiment 1: substrate preference selection for transphosphatidylation reactions
The method comprises the following steps:
(I) transphosphatidylation
(1) 10 mg of phosphatidylcholine was dissolved in 1 mL of cyclopentyl methyl ether to obtain an organic phase.
(2) 0.12 g D-galactose was dissolved in 1 mL citric acid-sodium citrate buffer (pH 6.0, 0.1M) to give an aqueous phase.
(3) The organic phase and the aqueous phase were mixed at a volume ratio of 1:1, and 1.4U of PLD was added to form a biphasic reaction condition, and the mixture was sealed in a brown vial.
(4) The brown bottle is put into a constant temperature water bath kettle and is subjected to water bath reaction for 10 hours under the conditions of 40 ℃ and 200 r.
(5) After the reaction is finished, centrifuging (8000 r, 5 min) to obtain supernatant A.
And (3) replacing the D-galactose in the step (2) with 0.21 g of neoagarobiose, 0.49 g of neoagarotetraose and 1.5 g of 1-15 agaro-oligosaccharide respectively (under the same conditions), and obtaining a supernatant B, a supernatant C and a supernatant D.
(II) carrying out thin-layer chromatography analysis on the prepared supernatant A, the prepared supernatant B, the prepared supernatant C and the prepared supernatant D:
(1) samples with the volume of a capillary tube of 0.5mm are sampled, and the samples are dried by a blower after each sample sampling.
(2) Placing the silica gel plate with the spotted sample in a spreading cylinder containing a spreading agent, wherein the formula of the spreading agent is chloroform: methanol: glacial acetic acid: water =50:25:6:2 (v: v: v: v).
(3) After about 20 min, the silica gel plate was taken out, dried by a blower, and then placed in an iodine jar, and the experimental results were observed later.
From the thin layer chromatography analysis result diagram (as shown in fig. 1), it can be seen that in the transphosphatidylation reaction taking agar oligosaccharides with different polymerization degrees as raw materials, the transesterification reaction taking neoagarobiose as a main component is more thorough, and the substrate PC is almost completely degraded. The transesterification reaction with D-galactose is relatively thorough, the transesterification reaction with neoagarotetraose is relatively weak, and the mixed agar oligosaccharide has no transesterification reaction. Therefore, the agaro-oligosaccharides obtained by the subsequent transphosphatidylation reaction are determined to be D-galactose and neoagarobiose.
Example 1: synthesis of phosphatidyl-agaropectin oligosaccharide by PLD (pulsed laser deposition) catalytic enzyme method
The method comprises the following steps:
(1) 10 mg of phosphatidylcholine was dissolved in 1 mL of cyclopentyl methyl ether to obtain an organic phase.
(2) 0.12 g D-galactose was dissolved in 1 mL citric acid-sodium citrate buffer (pH 6.0, 0.1M) to give an aqueous phase.
(3) The organic phase and the aqueous phase were mixed at a volume ratio of 1:1, and 1.4U of PLD was added to form a biphasic reaction condition, and the mixture was sealed in a brown vial.
(4) The brown bottle is put into a constant temperature water bath kettle and is subjected to water bath reaction for 10 hours under the conditions of 40 ℃ and 200 r.
(5) After the reaction is finished, centrifuging (8000 r, 5 min) to obtain supernatant, and obtaining the phosphatidyl-agaropectin oligosaccharide dissolved in the organic solvent.
(6) After nitrogen blowing, the high-concentration phosphatidyl-agaropectin oligosaccharide is obtained, and the structural formula is shown in figure 3.
Replacing the D-galactose in the step (2) with 0.21 g of neoagarobiose (under the same other conditions), and preparing the phosphatidyl-neoagarobiose, wherein the structural formula of the phosphatidyl-neoagarobiose is shown in figure 4.
The relative molecular mass of the two phosphatidyl-agaropectides is measured by the MS method, the results are shown in figures 5 and 6, the analysis result is consistent with the calculation result of the corresponding molecular ion peak (M phosphatidyl-D galactose is approximately 851, M phosphatidyl-neoagaropectide is approximately 995), and the mass spectrometry result and the liquid phase product peak result can both indicate that the target phosphatidyl glycoside is generated after transesterification reaction, so that the phosphatidyl-D galactose and the phosphatidyl-neoagaropectide are determined to be prepared.
Experiment 2: key parameter of transphosphatidylation preparation process
The parameters critical to the phospholipid acylation reaction include: in the transesterification, the molar ratio of PC to sugar (1: 20, 1:30, 1:40, 1:50, 1: 60), the amount of PLD added (0.2, 0.6, 1, 1.4, 1.8U), the transesterification time (4, 6, 8, 10, 12 h) and the volume ratio of organic phase to aqueous phase in the biphasic reaction system (1: 3, 1:2, 1:1, 2: 1, 3: 1). Regulating and controlling the 4 factors in the reaction system, detecting the synthesis conversion rate by adopting an HPLC-ELSD method, and finally determining the optimal synthesis condition of the phosphatidyl-agaropectin oligosaccharide. When the molar ratio of PC to sugar is 1:50, the amount of PLD enzyme is 1.4U, the transesterification reaction time is 10 hours, and the volume ratio of the organic phase to the aqueous phase is 1:1, the conversion rate of phosphatidyl-D galactose can reach 85% and the conversion rate of phosphatidyl-neoagarobiose can reach 96% under the optimal reaction conditions (FIG. 7). Experimental results show that when the neoagarobiose is used as a raw material for the transphosphatidylation reaction, the conversion rate of phosphatidyl-neoagarobiose is obviously higher than that of D-galactose.
The above examples are provided to those of ordinary skill in the art to fully disclose and describe how to make and use the claimed embodiments, and are not intended to limit the scope of the disclosure herein. Modifications apparent to those skilled in the art are intended to be within the scope of the appended claims.
Claims (10)
1. A preparation method of phosphatidyl-agar oligosaccharide is characterized in that: phosphatidyl choline and agar oligosaccharide are catalyzed by phospholipase D in a two-phase reaction system to generate transphosphatidylation action, and the phosphatidyl-agar oligosaccharide is synthesized; the agar oligosaccharide is selected from D-galactose and neoagarobiose; the phospholipase D is selected from PLDr 34.
2. The method for preparing phosphatidyl-agaropectin oligosaccharide according to claim 1, wherein the method comprises the following steps: the fatty acid chains on the phosphatidylcholine are palmitic acid C16:0 and linoleic acid C18:2 respectively.
3. The method for preparing phosphatidyl-agaropectin oligosaccharide according to claim 1, wherein the method comprises the following steps: dissolving the phosphatidylcholine in an organic solvent to obtain an organic phase; the organic solvent is selected from methyl ether, ethyl ether, cyclopentyl methyl ether, ethyl acetate, butyl acetate or ethyl butyrate; the concentration of the phosphatidylcholine is 10-100 mg/mL.
4. The method for preparing phosphatidyl-agaropectin oligosaccharide according to claim 1, wherein the method comprises the following steps: the agar oligosaccharide is dissolved in an aqueous solution to be used as a water phase; the water solution is selected from citric acid-sodium citrate buffer solution with the pH value of 4.0-6.0.
5. The method for preparing phosphatidyl-agaropectin oligosaccharide according to claim 1, wherein the method comprises the following steps: the neoagarobiose is prepared by degrading agarose by beta agarase AgWH50B and/or beta agarase AgWH 50C.
6. The method for preparing phosphatidyl-agaropectin oligosaccharide according to claim 1, wherein the method comprises the following steps: in the two-phase reaction system, the molar ratio of phosphatidylcholine to agar oligosaccharide is 1: 45-55; the volume ratio of the organic phase to the water phase is 1: 0.8-1.2; the enzyme adding amount of the phospholipase D is 1.0-1.5U.
7. The method for preparing phosphatidyl-agaropectin oligosaccharide according to claim 6, wherein the method comprises the following steps: the molar ratio of the phosphatidylcholine to the agar oligosaccharide is 1: 50; the volume ratio of the organic phase to the aqueous phase is 1: 1; the enzyme adding amount of the phospholipase D is 1.4U.
8. The method for preparing phosphatidyl-agaropectin oligosaccharide according to claim 1, wherein the method comprises the following steps: the specific reaction conditions for catalyzing the transphosphatidylation are as follows: the reaction system is subjected to water bath reaction at 37-42 ℃ for 8-12 h.
9. The phosphatidyl-agar oligosaccharide prepared by the preparation method of any one of claims 1 to 8.
10. Use of the phosphatidyl-agaropectide of claim 9 as an active substance in the preparation of liposomes, drug delivery.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111600499.6A CN114214377B (en) | 2021-12-24 | 2021-12-24 | Phosphatidyl-agar oligosaccharide and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111600499.6A CN114214377B (en) | 2021-12-24 | 2021-12-24 | Phosphatidyl-agar oligosaccharide and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114214377A true CN114214377A (en) | 2022-03-22 |
CN114214377B CN114214377B (en) | 2024-03-08 |
Family
ID=80705935
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111600499.6A Active CN114214377B (en) | 2021-12-24 | 2021-12-24 | Phosphatidyl-agar oligosaccharide and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114214377B (en) |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4624919A (en) * | 1983-04-11 | 1986-11-25 | Meito Sangyo Kabushiki Kaisha | Enzymatic production of phospholipid-saccharide derivatives |
JPH0656856A (en) * | 1993-04-16 | 1994-03-01 | Meito Sangyo Kk | Phospholipid derivative |
JPH07188274A (en) * | 1993-12-27 | 1995-07-25 | Honen Corp | Novel galactose derivative |
JPH10226616A (en) * | 1997-02-18 | 1998-08-25 | Noevir Co Ltd | Skin preparation for external use |
WO2000018945A1 (en) * | 1998-10-01 | 2000-04-06 | Albany Molecular Research, Inc. | Transphosphatidylation catalized by phospholipase d in anhydrous organic solvents in the presence of ion-exchange resin |
US20080096253A1 (en) * | 2004-06-09 | 2008-04-24 | Alexander Sunguroff | Methods of making nanotechnological and macromolecular biomimetic structures |
US20090238811A1 (en) * | 2002-09-09 | 2009-09-24 | Mcdaniel C Steven | Enzymatic Antimicrobial and Antifouling Coatings and Polymeric Materials |
WO2015041498A1 (en) * | 2013-09-23 | 2015-03-26 | 다인바이오 주식회사 | Immune enhancement or anticancer composition containing neoagarooligosaccharide |
CN105255967A (en) * | 2015-11-12 | 2016-01-20 | 福州大学 | Enzymolysis preparation method of new agaro oligosaccharides |
US20160265012A1 (en) * | 2013-10-14 | 2016-09-15 | Korea University Research And Business Foundation | Agarooligosaccharide hydrolase and method for producing 3,6-anhydro-l-galactose and galactose from agarose by using same |
KR20180041377A (en) * | 2016-10-14 | 2018-04-24 | 명지대학교 산학협력단 | A Novel alpha-neoagarobiose hydrolase from Gayadomonas joobiniege G7 and use thereof |
CN110564708A (en) * | 2019-10-19 | 2019-12-13 | 中国海洋大学 | Recombinant phospholipase D and application thereof in synthesis of phosphatidylserine or other phospholipids |
WO2020133314A1 (en) * | 2018-12-29 | 2020-07-02 | 邦泰生物工程(深圳)有限公司 | Phospholipase d mutant, use thereof and method for preparing phosphatidylserine by means of same |
CN111514152A (en) * | 2020-05-18 | 2020-08-11 | 中国海洋大学 | Application of n-3PUFA phosphatidyl glycoside in preparation for improving blood brain barrier damage |
CN111621535A (en) * | 2020-05-18 | 2020-09-04 | 中国海洋大学 | Preparation method and application of phosphatidyl glycoside |
-
2021
- 2021-12-24 CN CN202111600499.6A patent/CN114214377B/en active Active
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4624919A (en) * | 1983-04-11 | 1986-11-25 | Meito Sangyo Kabushiki Kaisha | Enzymatic production of phospholipid-saccharide derivatives |
JPH0656856A (en) * | 1993-04-16 | 1994-03-01 | Meito Sangyo Kk | Phospholipid derivative |
JPH07188274A (en) * | 1993-12-27 | 1995-07-25 | Honen Corp | Novel galactose derivative |
JPH10226616A (en) * | 1997-02-18 | 1998-08-25 | Noevir Co Ltd | Skin preparation for external use |
WO2000018945A1 (en) * | 1998-10-01 | 2000-04-06 | Albany Molecular Research, Inc. | Transphosphatidylation catalized by phospholipase d in anhydrous organic solvents in the presence of ion-exchange resin |
US20090238811A1 (en) * | 2002-09-09 | 2009-09-24 | Mcdaniel C Steven | Enzymatic Antimicrobial and Antifouling Coatings and Polymeric Materials |
US20080096253A1 (en) * | 2004-06-09 | 2008-04-24 | Alexander Sunguroff | Methods of making nanotechnological and macromolecular biomimetic structures |
WO2015041498A1 (en) * | 2013-09-23 | 2015-03-26 | 다인바이오 주식회사 | Immune enhancement or anticancer composition containing neoagarooligosaccharide |
US20160265012A1 (en) * | 2013-10-14 | 2016-09-15 | Korea University Research And Business Foundation | Agarooligosaccharide hydrolase and method for producing 3,6-anhydro-l-galactose and galactose from agarose by using same |
CN105255967A (en) * | 2015-11-12 | 2016-01-20 | 福州大学 | Enzymolysis preparation method of new agaro oligosaccharides |
KR20180041377A (en) * | 2016-10-14 | 2018-04-24 | 명지대학교 산학협력단 | A Novel alpha-neoagarobiose hydrolase from Gayadomonas joobiniege G7 and use thereof |
WO2020133314A1 (en) * | 2018-12-29 | 2020-07-02 | 邦泰生物工程(深圳)有限公司 | Phospholipase d mutant, use thereof and method for preparing phosphatidylserine by means of same |
CN110564708A (en) * | 2019-10-19 | 2019-12-13 | 中国海洋大学 | Recombinant phospholipase D and application thereof in synthesis of phosphatidylserine or other phospholipids |
CN111514152A (en) * | 2020-05-18 | 2020-08-11 | 中国海洋大学 | Application of n-3PUFA phosphatidyl glycoside in preparation for improving blood brain barrier damage |
CN111621535A (en) * | 2020-05-18 | 2020-09-04 | 中国海洋大学 | Preparation method and application of phosphatidyl glycoside |
Non-Patent Citations (1)
Title |
---|
钟秀丽: "磷脂酶D的细胞信号转导作用", 《植物生理与分子生物学学报》, no. 5, pages 451 - 460 * |
Also Published As
Publication number | Publication date |
---|---|
CN114214377B (en) | 2024-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tang et al. | One-pot N-glycosylation remodeling of IgG with non-natural sialylglycopeptides enables glycosite-specific and dual-payload antibody–drug conjugates | |
Thiem et al. | Chemoenzymatic syntheses of sialyloligosaccharides with immobilized sialidase | |
Siebenhaller et al. | Integrated process for the enzymatic production of fatty acid sugar esters completely based on lignocellulosic substrates | |
Fauré et al. | Synthesis of a library of xylogluco-oligosaccharides for active-site mapping of xyloglucan endo-transglycosylase | |
Galan et al. | Ionic-liquid-based MS probes for the chemo-enzymatic synthesis of oligosaccharides | |
Yano et al. | Total synthesis of Myc-IV (C16: 0, S) via automated electrochemical assembly | |
Song et al. | Phospholipase D (PLD) catalyzed synthesis of phosphatidyl-glucose in biphasic reaction system | |
KR20000067921A (en) | Process for the preparation of sphingolipids and sphingolipid derivatives | |
JP2020183383A (en) | Hexose derivative, its preparation and use | |
CN114214377B (en) | Phosphatidyl-agar oligosaccharide and preparation method thereof | |
Filice et al. | Preparation of linear oligosaccharides by a simple monoprotective chemo-enzymatic approach | |
Gao et al. | Regioselective synthesis of dimeric (gemini) and trimeric sugar‐based surfactants | |
Kuhn et al. | Properties of Galactosyltransferase‐Enriched Vesicles of Golgi Membranes from Lactating‐Rat Mammary Gland | |
Bavaro et al. | Flow-based biocatalysis: Application to peracetylated arabinofuranosyl-1, 5-arabinofuranose synthesis | |
Kakde et al. | Synthesis of Cell-Permeable N-Acetylhexosamine 1-Phosphates | |
US20230184751A1 (en) | Flow chemistry system and method for carbohydrate analysis | |
CN114410717A (en) | Phosphatidyl glucoside and preparation method and application thereof | |
CN111289592B (en) | Microarray sensor for simultaneously detecting various saccharides in plant body in vivo and preparation and application thereof | |
Black et al. | Synthesis of phalluside-1 and Sch II using 1, 2-metallate rearrangements | |
安藤弘宗 et al. | A synthetic challenge to the diversity of gangliosides for unveiling their biological significance | |
DE3617399C2 (en) | ||
US20190300920A1 (en) | Fermentative production and isolation of stable isotope labeled metabolites from microbial cell walls and/or cell membranes | |
Rajapaksha et al. | Enzyme Related Synthesis of Lipids and Fabrication of Planar Lipid Membranes | |
Giotta et al. | Binding of spin-labeled local anesthetics to lobster nerves | |
Matsumaru et al. | Fungal β‐Mannosyloxymannitol Glycolipids and Their Analogues: Synthesis and Mincle‐Mediated Signaling Activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |